FDA approves first once-monthly buprenorphine injection for OUD
FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for moderate-to-severe opioid use disorder...
List view / Grid view
FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for moderate-to-severe opioid use disorder...
The EMA has granted a Marketing Authorization for Zubsolv, a novel rapidly-disintegrating treatment option for opioid dependence...
30 June 2016 | By Victoria White, Digital Content Producer
Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
22 April 2015 | By Victoria White
Orexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence...